Skip to Content

Join the 'Neostigmine' group to help and get support from people like you.

Neostigmine News

Safeguards May Be Reducing Serious Catheter Infections

Posted 23 Jan 2017 by Drugs.com

MONDAY, Jan. 23, 2017 – Improved catheter safety measures in hospitals significantly reduce bloodstream infections and health care costs, a new study indicates. "Safety interventions are a win-win for both patients and hospitals," said study leader Dr. Teryl Nuckols of Cedars-Sinai Medical Center in Los Angeles. She is director of the center's division of general internal medicine. More than 60,000 primary bloodstream infections related to central venous catheters occur each year in the United States. About 12 percent of these infections end in death, according to background notes with the study. These catheters, also known as central lines, are widely used in intensive care units. They're placed in large veins in the arm, chest, neck or groin to deliver medications, fluids or blood to patients. To prevent serious infections, hospitals have introduced new safety procedures in recent ... Read more

Related support groups: Infections, Urinary Tract Infection, Bladder Infection, Trimethoprim, Nitrofurantoin, Macrobid, Kidney Infections, Elmiron, Phenazopyridine, Prevention of Bladder infection, Potassium Citrate, Macrodantin, Pyridium, Sodium Bicarbonate, Bethanechol, Methenamine, Azo-Standard, Hiprex, Candida Urinary Tract Infection, Uricalm

Flamel Technologies Announces FDA Approval of Bloxiverz

Posted 5 Jun 2013 by Drugs.com

LYON, FRANCE – (Marketwire) – 06/03/2013 – Flamel Technologies today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for Bloxiverz (neostigmine methylsulfate), a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch Bloxiverz in July 2013 in 0.5 and 1.0 mg/mL strengths. "We are extremely excited and pleased to receive this FDA approval for Bloxiverz, the first product from the portfolio of Éclat products acquired in March 2012," said Mike Anderson, Chief Executive Officer of Flamel. Bloxiverz is the first FDA-approved version of neostigmine, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Today, ... Read more

Related support groups: Neostigmine, Reversal of Nondepolarizing Muscle Relaxants

Ask a Question

Further Information

Related Condition Support Groups

Reversal of Neuromuscular Blockade, Myasthenia Gravis, Urinary Retention, Reversal of Nondepolarizing Muscle Relaxants

Related Drug Support Groups

Bloxiverz, Prostigmin, Prostigmin Bromide

Neostigmine Patient Information at Drugs.com